The mutational spectrum of TP53 cases included in our study is less complex than in cases with MDS, which may explain differences in the pathophysiology of a TP53 mutation in thrombocytopenia cases compared with MDS cases. This evidence concerns the gene TP53 and myelodysplastic syndrome.